

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Valentis, Inc.	11/14/2006

RECEIVING PARTY DATA

Name:	Genetronics, Inc.
Street Address:	11494 Sorrento Valley Road
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92121

PROPERTY NUMBERS Total: 14

Property Type	Number
Application Number:	10400053
Patent Number:	6040295
Patent Number:	6514947
Patent Number:	6534483
Application Number:	10234406
Application Number:	11217266
Patent Number:	5902802
Patent Number:	5932241
Patent Number:	5958894
Patent Number:	6235310
Patent Number:	6121457
Patent Number:	6245520
Patent Number:	6271209
Patent Number:	6271206

CORRESPONDENCE DATA

PATENT

500180855

REEL: 018524 FRAME: 0655

CH \$560.00 10400053

Fax Number: (832)446-2424

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 832 446 2400

Email: WCPatent@counselip.com

Correspondent Name: Marilyn M. Huston

Address Line 1: 20333 SH 249 Suite 600

Address Line 4: Houston, TEXAS 77070

ATTORNEY DOCKET NUMBER:

213-0001

NAME OF SUBMITTER:

Marilyn M. Huston

Total Attachments: 3

source=Genetronics-Inovio Technology Assignment 111406#page1.tif

source=Genetronics-Inovio Technology Assignment 111406#page2.tif

source=Genetronics-Inovio Technology Assignment 111406#page3.tif

TECHNOLOGY ASSIGNMENT

THIS TECHNOLOGY ASSIGNMENT, effective as of the date of execution, is by and between Valentis, Inc., a Delaware corporation, with offices at 863A Mitten Rd., Burlingame, CA 94010 ("Valentis") and Genetronics, Inc., a California corporation and wholly owned subsidiary of Inovio Biomedical Corporation ("Genetronics").

WHEREAS, on October 16, 2006, Valentis completed a Technology Transfer Agreement ("the Agreement") with Genetronics whereby Valentis sold to Genetronics certain patents, trademarks and intellectual property rights relating to Valentis' PINC® polymer delivery system, and certain of its cationic lipid and gene expression technologies, together set out in Appendix A hereto ("the Valentis Technology"), and

WHEREAS, in furtherance of the aforementioned Agreement, Valentis has agreed to and desires to transfer, assign, convey, deliver and vest from Valentis to Genetronics, a full and complete interest in the Valentis Technology, pursuant to the terms of the Agreement,

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Valentis hereby assigns and transfers to Genetronics, its successors and assigns, Valentis' entire right, title and interest to the Valentis Technology, under the terms of the Agreement, not only in the United States and its territorial possessions, but in all foreign countries, including any and all patents and applications set out in Appendix A, and to any continuation, division, renewal, substitute or reissue thereof or any legal equivalent thereof in the United States or a foreign country for the full term or terms for which the same may be granted, including all priority rights under the International Convention.


Valentis hereby authorizes and requests the United States Commissioner of Patents and Trademarks, and any officials of foreign countries whose duty it is to issue patents or any legal equivalent thereof, to issue Letters Patent stemming from applications set out in Appendix A to Genetronics, its successors and assigns, as fully defined under the provisions of the Agreement.

IN WITNESS WHEREOF, this TECHNOLOGY ASSIGNMENT is executed by the duly authorized representative of Valentis.

Executed and delivered this 14 day of November, 2006.

Valentis, Inc.

By:


Benjamin F. McGraw, III
President & Chief Executive Officer

CERTIFICATE OF ACKNOWLEDGMENT

THE STATE OF CALIFORNIA §
COUNTY OF SAN MATEO §

Personally appeared before me this 14th day of November, 2006, Benjamin F. McGraw, III, to me known to be the person whose name is subscribed to the foregoing instrument, and acknowledged that the present instrument is signed, sealed and delivered as a free and voluntary act and deed for the uses and purposes therein set forth.

Shalini Kalra
Notary Public in and for the State of California

My Commission expires 9-19-10



Appendix A:

GeneSwitch IP (Co-Owned with Baylor)	
US 10/400,053 (<i>pending</i>)	"Improved System for Regulation of Transgene Expression"
CA2,423,093 (<i>pending</i>)	
EP2001-977218.5 (<i>pending</i>)	

PINC PATENTS	
6,040,295	Formulated NA Compositions and Methods of Administering the Same For Gene Therapy
6,514,947	
AU703419B2	
AU744010B2	
CA2210132 (<i>pending</i>)	
EP95944270.8 (<i>pending - grant procedures underway</i>)	
JP521697/96 (<i>pending</i>)	
6,534,483	Protected One-Vial Formulation for Nucleic Acid Molecules, Methods of Making the Same by in-line mixing and Related Products and Methods
CA 2,340,416 (<i>pending</i>)	
EP1104309 B1 (AU, DE, FR, GB, IE, NE)	
JP 2000-564589 (<i>pending</i>)	
US 10/234,406 (2003-0109478 - <i>pending</i>)	Nucleic Acid Formulations for Gene Delivery and Methods of Use
CA 2,401,327 (<i>pending</i>)	
EP 01918339.1, (<i>pending</i>)	
JP 2003-525912A (<i>pending</i>)	
US 11/217,266, published as US 2006-0013883 (<i>pending</i>)	Improved Poloxamer Compositions for Nucleic Acid Delivery
CA 2,401,239 (<i>pending</i>)	
EP 01913279.4, (<i>pending</i>)	
JP 2003-525613A (<i>pending</i>)	

Cationic Lipid Patents	
5,902,802	Cationic Amphiphiles
5,932,241	Cationic Lipid DNA Complexes for Gene Targeting
5,958,894	Amphiphilic Biguanine Derivatives
6,235,310	Methods of Delivery using Cationic Lipids and Helper Lipids
6,121,457	Compositions and Methods using Novel Substituted Imidazolium Lipids
6,245,520	Methods for Introducing Nucleic Acids into Mammalian cells using Imidazolium Lipids
6,271,209	Cationic Lipid Formulation Delivering Nucleic Acid to Peritoneal Tumors
6,271,206	Sonic Nebulized Nucleic Acid/Cationic Liposome Complexes and Methods for Pulmonary Gene Delivery

TRADEMARKS	
US2927956	PINC®
US 2,496,464	GENESWITCH ®
CTM 514,604	GENESWITCH ® registered in the European Community
CTM 514,505	DNAVAX® registered in the European Community
CTM 1,184,787	DENDRIVAX® registered in the European Community
CTM 514,562	MULTIVAX® registered in the European Community